These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 15289811)
1. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer. Johnstone PA; Williams SR; Riffenburgh RH Prostate Cancer Prostatic Dis; 2004; 7(3):263-7. PubMed ID: 15289811 [TBL] [Abstract][Full Text] [Related]
2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Wong WW; Schild SE; Vora SA; Halyard MY Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536 [TBL] [Abstract][Full Text] [Related]
3. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
4. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? King CR; Presti JC; Gill H; Brooks J; Hancock SL Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146 [TBL] [Abstract][Full Text] [Related]
5. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
6. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
7. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life]. Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749 [TBL] [Abstract][Full Text] [Related]
8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
9. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878 [TBL] [Abstract][Full Text] [Related]
10. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779 [TBL] [Abstract][Full Text] [Related]
11. [Effect of PSA nadir and the time to nadir in the disease-free period in localized prostatic carcinoma treated with radical radiation]. Cambeiro M; Azinovic I; Villafranca E; Moreno-Jiménez M; Cañón R; Aristu JJ; Beltrán C; López-Picazo JM; Fernández J; Rebollo J Rev Med Univ Navarra; 2001; 45(1):20-8. PubMed ID: 11488204 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Horwitz EM; Levy LB; Thames HD; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA Cancer; 2006 Oct; 107(7):1496-502. PubMed ID: 16944536 [TBL] [Abstract][Full Text] [Related]
14. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504 [TBL] [Abstract][Full Text] [Related]
15. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml. Herold D; Hanks G; Movsas B; Hanlon A Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052 [TBL] [Abstract][Full Text] [Related]
16. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
17. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738 [TBL] [Abstract][Full Text] [Related]
18. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]